Mai-wei-yang-fei decoction protects against pulmonary fibrosis by reducing telomere shortening and inhibiting AECII senescence via FBW7/TPP1 regulation.

Jing Wang, Yang Zhao, Yun Wei, Tingyuan Li, Tongxing Huang, Tingyu Pan, Jieyu Wu, Le Bai, Dongwei Zhu, Qi Zhao, Zhichao Wang, Fanchao Feng, Xianmei Zhou

Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China. · pubmed

Paper

Abstract

Pulmonary fibrosis (PF) is a fatal disease associated with ageing. The senescence of alveolar epithelial type II cells (AECIIs) can drive PF. Therefore, reducing AECII senescence is a promising treatment to prevent PF. Mai-wei-yang-fei decoction (MWYF) has shown significant clinical efficacy in the treatment of patients with PF. However, its mechanism of action remains unclear.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Mai-wei-yang-fei decoction reduces telomere shortening and inhibits AECII senescence, potentially offering a therapeutic approach to pulmonary fibrosis. The paper addresses the senescence of alveolar epithelial cells, which is a key aspect of aging and age-related diseases, thus contributing to the understanding of mechanisms that could mitigate age-related decline.

Author of this paper? Send a correction.